Sort
4,870 grants matching “glp 1”
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
$297,759Samirkumar Patel · Moonlight Therapeutics, Inc. · R42 · FY2020 · AI
Allosteric modulators of the glucagon-like peptide-1 receptor
$297,379Kevin D Niswender · Vanderbilt University · R01 · FY2014 · GM
Development Control in C. elegans
$297,357Min Han · University Of Colorado · R01 · FY2020 · GM
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION
$296,909Emory University · R01 · FY2003 · DK
Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes
$296,853Daniel J Lerner · Senseion, Llc · R43 · FY2019 · DK
Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs
$296,845Michelle M. Butler · Microbiotix, Inc · R43 · FY2017 · AI
Catalytic antioxidant for toxic inhaled chemicals
$296,766Carl W White · University Of Colorado Denver · U54 · FY2012 · ES
Toward Repurposing a Commonly-Used Medication for the Treatment of Pediatric Severe Obesity
$296,647Claudia K Fox · University Of Minnesota · R01 · FY2024 · DK
A novel thermogel for topical treatment of ulcerative colitis with microbialmetabolite mimicry.
$296,475Jeffrey Linhardt · Intact Therapeutics, Inc. · R43 · FY2023 · DK
CHANGING THE NATURAL HISTORY OF TYPE 2 DIABETES â âCHANGEâ STUDY
$296,473Lawrence S Phillips · Emory University · R01 · FY2025 · DK
Sustained Release intravitreal VEGFR inhibition to prevent blindness
$296,405Thomas J. Smith · Auritec Pharmaceuticals, Inc. · R43 · FY2012 · EY
Clinical and Informatics Research on Large Clinical Databases
$296,170Seo Baik · National Library Of Medicine · ZIA · FY2019 · LM
Glucagon-like peptide-1 agonist effects on energy balance in hypothalamic obesity
$296,126Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2018 · DK
FGF-2 mimetic peptides as pleuripotent mitigators of ARS and DEARE
$296,078Paul Okunieff · University Of Maryland Baltimore · U19 · FY2022 · AI
Smart CSF Delivery System for CNS Drug Therapy for Leptomeningeal Disease
$295,851Marcie A Glicksman · Enclear Therapies, Inc. · R43 · FY2024 · CA
Molecular Basis of Antidiabetogenic Hormone Action
$295,750George G Holz · New York University School Of Medicine · R01 · FY2007 · DK
A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases
$295,700Karl H Donn · Parion Sciences, Inc. · R44 · FY2024 · HL
Pre-clinical development of gene modified stem cells and CAR T-cells for HIV-1
$295,598Geoffrey Symonds · University Of California Los Angeles · U19 · FY2016 · AI
PDX-1 REGULATION OF PANCREAS DEVELOPMENT/DIFFERENTIATION
$295,317Doris A. Stoffers · University Of Pennsylvania · P01 · FY2010 · DK
Glucagon Biosynthesis and Metabolism
$295,240Joel F Habener · Massachusetts General Hospital · R01 · FY2007 · DK
Retinal Gene Therapy
$295,003Peter Colosi · National Eye Institute · ZIA · FY2011 · EY
Pathology
$294,422Thomas March · Lovelace Biomedical & Environmental Research Institute · U54 · FY2009 · NS
Function of ATP-sensitive Potassium Channels
$294,387Joseph Bryan · Baylor College Of Medicine · R01 · FY2006 · DK
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis
$294,150Michelle M. Butler · Microbiotix, Inc · R43 · FY2012 · AI
Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation
$294,109Carleton Hsia · Synzyme Technology, Inc. · U44 · FY2012 · NS